Acceptability of PC-1005 Gel Administered Rectally to HIV-1 Seronegative Adults at Three Different Volume Levels (MTN-037).
HIV prevention
MPT
microbicide
rectal
sexually transmitted infections
Journal
AIDS education and prevention : official publication of the International Society for AIDS Education
ISSN: 1943-2755
Titre abrégé: AIDS Educ Prev
Pays: United States
ID NLM: 9002873
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
25
8
2022
Statut:
ppublish
Résumé
Multipurpose prevention technologies (MPT) have been increasingly researched for their dual-purpose preventative properties against HIV and other STIs. The acceptability of PC-1005, a topical MPT candidate, was explored among men and women participating in the MTN-037 Phase I trial at two U.S. sites (Pittsburgh, PA, and Birmingham, AL). We triangulated quantitative and qualitative assessments of the acceptability of three volumes (4 mL, 16 mL, 32 mL) of PC-1005 administered rectally (N = 12; 6 males, 6 females). Participants rated overall gel acceptability on a scale of 1-10, with a median of 7.17 (
Identifiants
pubmed: 35994578
doi: 10.1521/aeap.2022.34.4.257
pmc: PMC9924357
mid: NIHMS1871492
doi:
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-271Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068633
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069494
Pays : United States
Références
AIDS Behav. 2022 May;26(5):1333-1346
pubmed: 34657218
AIDS Behav. 2018 Feb;22(2):388-401
pubmed: 28825142
AIDS Behav. 2020 Feb;24(2):607-616
pubmed: 30877580
Qual Health Res. 2017 Jul;27(8):1236-1248
pubmed: 28682740
AIDS Behav. 2014 May;18(5):820-5
pubmed: 24623069
AIDS Educ Prev. 2016 Feb;28(1):1-10
pubmed: 26829253
J Sex Res. 2016 Jul-Aug;53(6):633-41
pubmed: 26132717
Sex Transm Dis. 2007 Apr;34(4):224-9
pubmed: 16906126
Clin Infect Dis. 2017 Mar 1;64(5):614-620
pubmed: 27986684
Kolner Z Soz Sozpsychol. 2017;69(Suppl 2):107-131
pubmed: 28989188
Sex Transm Dis. 2007 Jan;34(1):15-9
pubmed: 16691157
Sex Transm Infect. 2008 Nov;84(6):483-7
pubmed: 19028952
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090
AIDS Behav. 2014 Sep;18(9):1734-45
pubmed: 24858481
Sex Transm Dis. 2016 Apr;43(4):249-54
pubmed: 26967302
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5459-66
pubmed: 27381393
PLoS One. 2011 Jan 05;6(1):e15835
pubmed: 21246052
Adv Drug Deliv Rev. 2015 Sep 15;92:27-38
pubmed: 25543007
Expert Opin Drug Deliv. 2014 Jan;11(1):69-82
pubmed: 24266648
AIDS Behav. 2013 Mar;17(3):1002-15
pubmed: 23114512
BJOG. 2014 Oct;121 Suppl 5:62-9
pubmed: 25335842
AIDS Behav. 2014 Sep;18(9):1726-33
pubmed: 24719200
Am J Public Health. 2004 Jul;94(7):1089-92
pubmed: 15226124
AIDS Res Hum Retroviruses. 2017 May;33(5):440-447
pubmed: 27824253
AIDS Care. 2014;26(12):1609-18
pubmed: 25022198
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):489-496
pubmed: 27437826
AIDS Behav. 2011 Apr;15 Suppl 1:S66-71
pubmed: 21331798
J Int AIDS Soc. 2021 Feb;24 Suppl 1:e25659
pubmed: 33605533
AIDS Educ Prev. 2021 Oct;33(5):361-376
pubmed: 34596427
AIDS Behav. 2016 Nov;20(11):2644-2653
pubmed: 26837628
Contraception. 2018 Mar;97(3):277-284
pubmed: 29055782
Curr Opin HIV AIDS. 2012 Nov;7(6):534-41
pubmed: 23032737
BJOG. 2014 Oct;121 Suppl 5:45-52
pubmed: 25335840
Arch Sex Behav. 2017 May;46(4):1101-1109
pubmed: 27129533
Curr HIV/AIDS Rep. 2013 Mar;10(1):89-102
pubmed: 23184582
PLoS One. 2016 Mar 10;11(3):e0147743
pubmed: 26963505
Trends Microbiol. 2015 Jul;23(7):429-436
pubmed: 25759332